Skip to main content
. 2018 Mar 2;9(3):349. doi: 10.1038/s41419-018-0387-2

Fig. 1. DNA vs. mRNA quantitative PCR results.

Fig. 1

The figure displays the kinetics of the leukemic cell burden in patients treated with Imatinib mesylate after the diagnosis in early chronic phase. (ah) The panels show the percentage of cancer cells (BCR-ABL1/BCR) as measured by gDNA qPCR (⊗DNA values, solid line) and RT–qPCR (▲RNA values, dashed line) in patients 1–8